Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02096081 · ClinicalTrials.gov registry record · Phase 4
The Treatment of Glabellar Frown Lines
A Phase 4 study, sponsored by Merz North America.
- Completed
- Registry status
- Phase 4
- Development phase
- 250
- Enrollment target
NCT02096081 is a Phase 4 study that has completed, run by Merz North America. The registered enrollment target is 250 participants.
The verdict
NCT02096081, a Phase 4 study, has completed, sponsored by Merz North America.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 250 participants
- Enrollment target
Study Summary
The purpose of this study is to show that two FDA-approved botulinum toxin drugs called Xeomin® and Botox® can reduce the severity of vertical lines (wrinkles) that appear between the eyebrows (glabellar frown lines).
Interventions
- DRUG OnabotulinumtoxinA
- DRUG IncobotulinumtoxinA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2014-02 |
| Est. Completion | 2014-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02096081
The ClinicalTrials.gov registry entry for NCT02096081 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merz North America, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which OnabotulinumtoxinA is the first listed.
NCT02096081 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02096081 about?
NCT02096081 is a clinical study titled "The Treatment of Glabellar Frown Lines". The purpose of this study is to show that two FDA-approved botulinum toxin drugs called Xeomin® and Botox® can reduce the severity of vertical lines (wrinkles) that appear between the eyebrows (glabellar frown lines).
What is the current status of trial NCT02096081?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 250 participants. The study started on 2014-02. Estimated completion is 2014-11.
What interventions are being tested in trial NCT02096081?
The interventions under investigation include: OnabotulinumtoxinA (DRUG), IncobotulinumtoxinA (DRUG).
Who is sponsoring clinical trial NCT02096081?
This trial is sponsored by Merz North America, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.